1
1
6
↑1
↓1
—6
Evidence suggests MDMA haslittle to no effecton Safety.
8 studies (8 claims)
Emerging evidence
Typical effective dose 112.5 (106.25–118.75) mgacross 2 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| MDMA-assisted psychotherapy | Increases - constitutes a substantial improvement | safety and efficacy | Human | — | Administered in up to three monthly 8-hour sessions (specific dosage not mentioned). | Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.cited 5× |
| MDMA-assisted psychotherapy | No effect - can be safely administered | safety in a clinical setting | Human | patients with treatment-resistant PTSD | Low-dose (25 mg plus 12.5 mg supplemental) or full-dose (125 mg plus 62.5 mg supplemental) MDMA administered during three experimental sessions. | A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD).cited 226× |
| MDMA-assisted psychotherapy | No effect - show favorable safety outcomes | safety outcomes | Human | patients with PTSD | Not specified in the abstract. | Progress and promise for the MDMA drug development program.cited 35× |
| co-administration of MDMA (100 mg) | No effect - did not improve the safety profile | safety profile | Human | 24 healthy subjects (12 women, 12 men) | 100 mg MDMA and 100 µg LSD | Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants.cited 23× |
| MDMA | No effect - often demonstrated no significant MVP safety signals | motor vehicle driving performance (MVP) safety | Human | experimental studies | Not specified (doses in experimental studies may not reflect real-world concentrations). | Effects of 3,4-methylenedioxymethamphetamine and methamphetamine on motor vehicle driving performance: A systematic review of experimental and observational studies.cited 1× |
| MDMA | Decreases - overwhelming MVP safety risks found | motor vehicle driving performance (MVP) safety | Human | observational studies | Not specified (doses in experimental studies may not reflect real-world concentrations). | Effects of 3,4-methylenedioxymethamphetamine and methamphetamine on motor vehicle driving performance: A systematic review of experimental and observational studies.cited 1× |
| psychedelic-assisted group therapy model utilizing MDMA and LSD | No effect - no serious adverse events occurred | safety | Human | patients with chronic complex post-traumatic stress disorder (c-PTSD), dissociative, and other post-traumatic disorders | Not specified | Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders.cited 25× |
| MDMA-assisted therapy (MDMA-AT) | No effect - secondary outcomes include changes in feasibility and safety measures | feasibility and safety measures | Human | participants who meet criteria with moderate-to-severe social anxiety disorder (SAD) of the generalized subtype | Two oral doses of MDMA (specific amount not stated). | Social anxiety and MDMA-assisted therapy investigation: a novel clinical trial protocol.cited 3× |
| MDMA-assisted therapy | No effect - resulted in | safety and side effect profile | Human | human-subject studies | Not specified | Review of potential psychedelic treatments for PTSD.cited 18× |